Bexxar Articles
Medicare reimbursement change criticized
17 December 2007
Expanded indication for GSK's Bexxar
10 January 2005
GSK acquires full rights for Bexxar from Corixa
20 December 2004
Corixa files sBLA in USA for Bexxar
12 July 2004
New Chemical Entities in 2003
19 January 2004
Corixa/GSK's Bexxar launched in the USA
11 August 2003
GSK wins protection for Ceftin antibiotic
12 May 2003
IDEC sues Corixa and GSK over Bexxar
3 March 2003
Monoclonal antibodies on the cusp of strong growth?
10 February 2003
EU launch of NHL drug Zevalin delayed
8 July 2002
Bexxar BLA decision will be appealed
10 June 2002
March - the turning point for biotech?
15 April 2002
Corixa says no Bexxar advisory in February.
21 January 2002
IDEC's Zevalin delayed by FDA request
14 January 2002
Amersham gets rights to Bexxar in Europe
31 October 2001
FDA asks for more data on Zevalin
11 May 2001
Stock Commentary - New York
29 March 2001
Corixa hit by FDA decision on Bexxar
20 March 2001
First launch for SmithKline Beecham's argatroban in HIT
15 November 2000
IDEC files for Zevalin OK in USA
3 November 2000
Coulter and SB get priority review for Bexxar
10 October 2000
SB, Coulter refile US Bexxar application
19 September 2000
Coulter on verge of refiling Bexxar NDA
7 August 2000
Coulter reacquires ex-USA Bexxar rights
26 April 2000
Stock Commentary New York
10 February 2000
Glaxo SmithKline, an R&D powerhouse and global number one
17 January 2000
Genentech and IDEC seek to broaden NHL indications for Rituxan
8 December 1999
Coulter and SB suffer on Bexxar resubmission
31 August 1999
SB sales increase 11% boosted by Avandia
21 July 1999
Coulter and SB file for US Bexxar approval
1 July 1999
Coulter to file for Bexxar approval soon
24 June 1999
Clinical trials round-up
10 June 1999
Diatide on road to profitability with its target-and-treat strategy
11 February 1999
SB To Jointly Commercialize Coulter's Cancer Therapy
8 December 1998
Coulter Begins Bexxar Re-Treatment Study
25 June 1998
Coulter Unveils Promising Bexxar Data
21 May 1998
Coulter Completes Patient Enrollment In Bexxar Trial
26 March 1998
Coulter Pharmaceutical On Road To Success
19 March 1998
Ph II Data With Coulter's Bexxar
11 December 1997
Coulter's Bexxar Data Sends Shares Up
19 November 1997
Bexxar Antibody Used 1st-Line In NHL
30 May 1997
Showing 1-57 of 57 articles
- 1
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
